US $30 million to help new drugs for neuralgia enter the clinical practice

Today, biointervene, a biomedical company based in San Diego, USA, announced the completion of the US $30 million round a financing, which will be used to promote the development of its first candidate drug bio-205 for the treatment of neuropathic pain, as well as the development of its product portfolio of A3 adenosine receptor (A3AR) agonists for the treatment of inflammatory and neurodegenerative diseases Biointerfere expects bio-205 to enter phase 1 clinical trials in the second half of this year Neuropathic pain is a complex chronic disease, usually called neuralgia It occurs in peripheral nerves and certain brain areas damaged by trauma, disease or toxins Common causes of neuropathic pain include neurological injury after surgery or trauma, herpes zoster infection, cancer, chemotherapy drugs, and neurological diseases (such as multiple sclerosis) and metabolic diseases (such as diabetes) Today, slayback Pharma, based in New Jersey, announced a $50 million round B financing The new funds will be used to expand and accelerate its rich generic and specialty pharmaceutical product lines Slayback focuses on the development of generic and specialty drugs So far, it has developed a highly differentiated product pipeline In the past two years, slayback has submitted multiple simplified new drug applications, many of which are potential first or second generic drugs on the market In January last year, the US FDA approved a simplified new drug application for its hydroxyprogesterone hydrochloride caproate injection to reduce the risk of premature delivery for pregnant women This is the first and only bottling of hydroxyprogesterone caproate injection to simplify new drug application and approval through FDA Recently, Dee company, which focuses on the precise diagnosis of tumor, announced the completion of 40 million US dollars financing The first round of financing after the spin off of thinkti diagnostics will be mainly used for product research and development, including the follow-up pipeline research and development of andis closed automation new generation sequencing technology (NGS) platform, the pipeline development of tumor early diagnosis products based on exosomes platform, and the pipeline expansion of third-party detection service products Thingdiagnosis has two business lines: the third-party medical inspection service and IVD (in vitro diagnosis) products It has laid out a series of product R & D pipelines, including the fields of early diagnosis, tumor associated diagnosis and tumor dynamic monitoring It has the world's first closed and fully automated ngs library preparation platform, and the world's leading development platform for early tumor diagnosis markers (exosomes) Based on these platforms, a number of China's first auxiliary diagnosis and accompanying diagnosis products are in the clinical trial stage or about to enter the clinical trial reference material: